astrazeneca - Search News

News

FluMist, AstraZeneca and Influenza vaccine

AstraZeneca begins DTC home delivery of self-administered FluMist vaccine

FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod allows adults up to 49 years old to use the nasal spray themselves, while parents and caregivers can give it to children aged 2 to 17.

Yahoo · 2d

Your flu vaccine can now be delivered to your home

AstraZeneca is making flu protection more convenient with the launch of an at-home delivery option for FluMist, its nasal spray flu vaccine, the company announced Friday. On the market since 2003, FluMist was previously only available at pharmacies or doctors' offices.

Yahoo Finance · 1d

AstraZeneca (LSE:AZN) Launches FluMist Home For At-Home Influenza Vaccination

AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter,

2don MSN

It’s now possible to give yourself a flu vaccine at home

For the first time, many people in the United States who want to protect themselves against the flu this respiratory virus ...

2don MSN

For first time, you can take flu vaccine yourself at home

AstraZeneca's FluMist Home received FDA approval as the first at-home flu vaccine. Adults ages 18 to 49 and children ages 2 to 17 can use the needle-free nasal spray. People with certain allergies or ...

AstraZeneca launches at-home FluMist nasal spray delivery

Starting Friday, Americans can order the nasal spray flu vaccine online and have it shipped directly to their home.

12d

AstraZeneca’s CFO On The Company’s Bet To Increase Its U.S. Business

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

26don MSN

AstraZeneca to build new Virginia plant as it re-hashes other U.S. investment plans

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration — though much of what it is ...